Transfusion therapy in sickle cell disease

Renaissance of Sickle Cell Disease Research in the Genome Era

Volumn , Issue , 2007, Pages 117-133

  Carolyn, Hoppe ^a   Robert, Adams ^b   Elliot, Vichinsky ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84967369199     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860947964_0008     Document Type: Chapter

References (126)

1. Arena JM (1935). Vascular accident and acute hemiplegia in sickle cell anemia. Am J Dis Child 49:722-723.
2. Stockman JA, Nigro MA, Mishkin MM, Oski FA (1972). Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med 287:846-849.
3. Prengler M, Pavlakis SG, Prohovnik I, Adams RJ (2002). Sickle cell disease: the neurological complications. Ann Neurol 51:543-552.
4. Earley CJ, Kittner SJ, Feeser BR, Gardner J, Epstein A, Wozniak MA, Wityk R, Stern BJ, Price TR, Macko RF, Johnson C, Sloan MA, Buchholz D (1998). Stroke in children and sickle-cell disease: Baltimore-Washington Cooperative Young Stroke Study. Neurology 51:169-176.
5. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM (1998). Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 91:288-294.
6. Powars D, Wilson B, Imbus C, Pegelow C, Allen J (1978). The natural history of stroke in sickle cell disease. Am J Med 65:461-471.
7. Armstrong FD, Thompson RJ Jr, Wang W, Zimmerman R, Pegelow CH, Miller S, Moser F, Bello J, Hurtig A, Vass K (1996). Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease. Neuropsychology committee of the Cooperative Study of Sickle Cell Disease. Pediatrics 97:864-870.
8. Steen RG, Xiong X, Mulhern RK, Langston JW, Wang WC (1999). Subtle brain abnormalities in children with sickle cell disease: relationship to blood hematocrit. Ann Neurol 45:279-286.
9. Steen RG, Reddick WE, Mulhern RK, Langston JW, Ogg RJ, Bieberich AA, Kingsley PB, Wang WC (1998). Quantitative MRI of the brain in children with sickle cell disease reveals abnormalities unseen by conventional MRI. J Magn Reson Imaging 8:535-543.
10. Kandeel AY, Zimmerman RA, Ohene-Frempong K (1996). Comparison of magnetic resonance angiography and conventional angiography in sickle cell disease: clinical significance and reliability. Neuroradiology 38:409-416.
11. Rodgers GP, Clark CM, Larson SM, Rapoport SI, Nienhuis AW, Schechter AN (1988). Brain glucose metabolism in neurologically normal patients with sickle cell disease. Regional alterations. Arch Neurol 45:78-82.
12. Reed W, Jagust W, Al-Mateen M, Vichinsky E (1999). Role of positron emission tomography in determining the extent of CNS ischemia in patients with sickle cell disease. Am J Hematol 60:268-272.
13. Powars DR, Conti PS, Wong WY, Groncy P, Hyman C, Smith E, Ewing N, Keenan RN, Zee CS, Harold Y, Hiti AL, Teng EL, Chan LS (1999). Cerebral vasculopathy in sickle cell anemia: diagnostic contribution of positron emission tomography. Blood 93:71-79.
14. Kirkham FJ, Calamante F, Bynevelt M, Gadian DG, Evans JP, Cox TC, Connelly A (2001). Perfusion magnetic resonance abnormalities in patients with sickle cell disease. Ann Neurol 49:477-485.
15. Pegelow CH, Macklin EA, Moser FG, Wang WC, Bello JA, Miller ST, Vichinsky EP, DeBaun MR, Guarini L, Zimmerman RA, Younkin DP, Gallagher DM, Kinney TR (2002). Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood 99:3014-3018.
16. Miller ST, Macklin EA, Pegelow CH, Kinney TR, Sleeper LA, Bello JA, DeWitt LD, Gallagher DM, Guarini L, Moser FG, Ohene-Frempong K, Sanchez N, Vichinsky EP, Wang WC, Wethers DL, Younkin DP, Zimmerman RA, DeBaun MR (2001). Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr 139:385-390.
17. Manfre L, Giarratano E, Maggio A, Banco A, Vaccaro G, Lagalla R (1999). MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. AJR Am J Roentgenol 173:1477-1480.
18. Powars DR (1990). Sickle cell anemia and major organ failure. Hemoglobin 14:573-598.
19. Koshy M, Thomas C, Goodwin J (1990). Vascular lesions in the central nervous system in sickle cell disease (neuropathology). J Am Assoc Minority Physicians 1:71-78.
20. Manci EA, Culberson DE, Yang YM, Gardner TM, Powell R, Haynes J Jr, Shah AK, Mankad VN (2003). Causes of death in sickle cell disease: an autopsy study. Br J Haematol 123:359-365.
21. Rothman SM, Fulling KH, Nelson JS (1986). Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann Neurol 20:684-690.
22. Bernaudin F, Verlhac S, Freard F, Roudot-Thoraval F, Benkerrou M, Thuret I, Mardini R, Vannier JP, Ploix E, Romero M, Casse-Perrot C, Helly M, Gillard E, Sebag G, Kchouk H, Pracros JP, Finck B, Dacher JN, Ickowicz V, Raybaud C, Poncet M, Lesprit E, Reinert PH, Brugieres P (2000). Multicenter prospective study of children with sickle cell disease: radiographic and psychometric correlation. J Child Neurol 15:333-343.
23. Wang W, Riester K, Gallagher D, et al. (1999). Progressive neurocognitive deficits occur in school-age children with sickle cell disease (SCD) in the absence of clinical or MRI evidence of infarction [abstract]. In: 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco.
24. Noll RB, Stith L, Gartstein MA, Ris MD, Grueneich R, Vannatta K, Kalinyak K (2001). Neuropsychological functioning of youths with sickle cell disease: comparison with non-chronically ill peers. J Pediatr Psychol 26:69-78.
25. Watkins KE, Hewes DK, Connelly A, Kendall BE, Kingsley DP, Evans JE, Gadian DG, Vargha-Khadem F, Kirkham FJ (1998). Cognitive deficits associated with frontal-lobe infarction in children with sickle cell disease. Dev Med Child Neurol 40:536-543.
26. Powars DR, Wong WY, Vachon LA (2001). Incomplete cerebral infarctions are not silent. J Pediatr Hematol Oncol 23:79-83.
27. Pegelow CH, Wang W, Granger S, Hsu LL, Vichinsky E, Moser FG, Bello J, Zimmerman RA, Adams RJ, Brambilla D (2001). Silent infarcts in children with sickle cell anemia and abnormal cerebral artery velocity. Arch Neurol 58:2017-2021.
28. Oyesiku NM, Barrow DL, Eckman JR, Tindall SC, Colohan AR (1991). Intracranial aneurysms in sicklecell anemia: clinical features and pathogenesis. J Neurosurg 75:356-363.
29. Vernet O, Montes JL, O’Gorman AM, Baruchel S, Farmer JP (1996). Encephaloduroarterio-synangiosis in a child with sickle cell anemia and moyamoya disease. Pediatr Neurol 14:226-230.
30. Adams RJ, Ohene-Frempong K, Wang W (2001). Sickle cell and the brain. Hematology (Am Soc Hematol Educ Program) 43:31-46.
31. Pavlakis SG, Prohovnik I, Piomelli S, DeVivo DC (1989). Neurologic complications of sickle cell disease. Adv Pediatr 36:247-276.
32. Dobson SR, Holden KR, Nietert PJ, Cure JK, Laver JH, Disco D, Abboud MR (2002). Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood 99:3144-3150.
33. Pavlakis SG (1989). Neurologic complications of sickle cell disease. Adv Pediatr 36:247-276.
34. Francis RB (1991). Large-vessel occlusion in sickle cell disease: pathogenesis, clinical consequences, and therapeutic implications. Med Hypotheses 35:88-95.
35. Hebbel RP, Vercellotti GM (1997). The endothelial biology of sickle cell disease. J Lab Clin Med 129:288-293.
36. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP (1997). Circulating activated endothelial cells in sickle cell anemia [see comments]. N Engl J Med 337:1584-1590.
37. Phelan MW, Faller DV (1996). Hypoxia decreases constitutive nitric oxide synthase transcript and protein in cultured endothelial cells. J Cell Physiol 167:469-476.
38. Shreeniwas R, Koga S, Karakurum M, Pinsky D, Kaiser E, Brett J, Wolitzky BA, Norton C, Plocinski J, Benjamin W, Burns DK, Goldstein A, Stern D (1992). Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 90:2333-2339.
39. Uchida K, Rackoff WR, Ohene-Frempong K, Kim HC, Reilly MP, Asakura T (1998). Effect of erythrocytapheresis on arterial oxygen saturation and hemoglobin oxygen affinity in patientswith sickle cell disease. Am J Hematol 59:5-8.
40. Powars DR, Meiselman HJ, Fisher TC, Hiti A, Johnson C (1994). Beta-S gene cluster haplotypes modulate hematologic and hemorheologic expression in sickle cell anemia. Use in predicting clinical severity. Am J Pediatr Hematol Oncol 16:55-61.
41. Hsu LL, Miller ST, Wright E, Kutlar A, McKie V, Wang W, Pegelow CH, Driscoll C, Hurlet A, Woods G, Elsas L, Embury S, Adams RJ (2003). Alpha thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia. J Pediatr Hematol Oncol 25:622-628.
42. Nagel RL, Steinberg MH (2001). Role of epistatic (modifier) genes in the modulation of the phenotypic diversity of sickle cell anemia. Pediatr Pathol Mol Med 20:123-136.
43. Kahn MJ, Scher C, Rozans M, Michaels RK, Leissinger C, Krause J (1997). Factor V Leiden is not responsible for stroke in patients with sickling disorders and is uncommon in African Americans with sickle cell disease. Am J Hematol 54:12-15.
44. Cumming AM, Olujohungbe A, Keeney S, Singh H, Hay CR, Serjeant GR (1999). The methylenetetrahydrofolate reductase gene C677T polymorphism in patients with homozygous sickle cell disease and stroke. Br J Haematol 107:569-571.
45. Andrade F, Annichino-Bizzacchi J, Saad S, Costa F, Arruda V (1998). Prothrombin mutant, factor V Leiden, and thermolabile variant of methylenetetrahydrofolate reductase among patients with sickle cell disease in Brazil. Am J Hematol 59:46-50.
46. Zimmerman SA, Ware RE (1998). Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease. Am J Hematol 59:267-272.
47. Carroll JE, McKie V, Kutlar A (1998). Are sickle cell disease patients with stroke genetically predisposed to the event by inheriting a tendency to high tumor necrosis factor levels? Am J Hematol 58:250.
48. Taylor JG, Tang D, Foster CB, Serjeant GR, Rodgers GP, Chanock SJ (2002). Patterns of low-affinity immunoglobulin receptor polymorphisms in stroke and homozygous sickle cell disease. Am J Hematol 69:109-114.
49. Tang DC, Prauner R, Liu W, Kim KH, Hirsch RP, Driscoll MC, Rodgers GP (2001). Polymorphisms within the angiotensinogen gene (GT-repeat) and the risk of stroke in pediatric patients with sickle cell disease: a case-control study. Am J Hematol 68:164-169.
50. Tam DA (1997). Protein C and protein S activity in sickle cell disease and stroke. J Child Neurol 12:19-21.
51. Houston PE, Rana S, Sekhsaria S, Perlin E, Kim KS, Castro OL (1997). Homocysteine in sickle cell disease: relationship to stroke. Am J Med 103:192-196.
52. Balasa VV, Gruppo RA, Gartside PS, Kalinyak KA (1999). Correlation of the C677T MTHFR genotype with homocysteine levels in children with sickle cell disease. J Pediatr Hematol Oncol 21:397-400.
53. Hoppe C, Klitz W, Noble J, Vigil L, Vichinsky E, Styles L (2003). Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood 101:2865-2869.
54. Hoppe C, Klitz W, Cheng S, Apple R, Steiner L, Robles L, Girard T, Vichinsky E, Styles L (2004). Gene interactions and stroke risk in children with sickle cell anemia. Blood 103:2391-2396.
55. Taylor JG, Tang DC, Savage SA, Leitman SF, Heller SI, Serjeant GR, Rodgers GP, Chanock SJ (2002). Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood 100:4303-4309.
56. Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH (2005). Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 37:435-440.
57. Adams R, McKie V, Nichols F, Carl E, Zhang DL, McKie K, Figueroa R, Litaker M, Thompson W, Hess D (1992). The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med 326:605-610.
58. Adams RJ, McKie VC, Carl EM, Nichols FT, Perry R, Brock K, McKie K, Figueroa R, Litaker M, Weiner S, Brambilla D (1997). Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol 42:699-704.
59. Nichols FT, Jones AM, Adams RJ (2001). Stroke prevention in sickle cell disease (STOP) study guidelines for transcranial Doppler testing. J Neuroimaging 11:354-362.
60. Adams RJ, Brambilla DJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Woods G, Olivieri N, Driscoll C, Miller S, Wang W, Hurlet A, Scher C, Berman B, Carl EM, Nichols FT, Roach S, Sutlar A, Wright E, Zimmerman RA, Gallager D, Waclawiw M, Bonds D (1998). Transfusion prevents first stroke in children with sickle cell disease: the “STOP” study. N Engl J Med 339:5-11.
61. Adams R, McKie V, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols F, Bonds D, Brambilla D (1998). Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonagraphy. N Engl J Med 339:5-11.
62. Adams RJ (2000). Lessons from the Stroke Prevention Trial in sickle cell anemia (STOP) study. J Child Neurol 15:344-349.
63. Abboud MR, Cure J, Granger S, Gallagher D, Hsu L, Wang W, Woods G, Berman B, Brambilla D, Pegelow C, Lewin J, Zimmermann RA, Adams RJ (2004). Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography findings enrolled in the STOP study. Blood 103:2822-2826.
64. Miller ST, Wright E, Abboud M, Berman B, Files B, Scher CD, Styles L, Adams RJ (2001). Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 139:785-789.
65. Vichinsky EP, Luban NL, Wright E, Olivieri N, Driscoll C, Pegelow CH, Adams RJ (2001). Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 41:1086-1092.
66. Clinical Alert (2004). NHLBI Stops Study Testing How Long Childrenwith Sickle Cell Anemia Should Have Blood Transfusions to Prevent Stroke. Bethesda, MD: National Institutes of Health, Health and Human Services.
67. Powars D (2000). Management of cerebral vasculopathy in children with sickle cell anaemia. Br J Haematol 108:666-678.
68. Pegelow CH, Adams RJ, McKie V, Abboud M, Berman B, Miller ST, Olivieri N, Vichinsky E, Wang W, Brambilla D (1995). Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 126:896-899.
69. Scothorn DJ, Price C, Schwartz D, Terrill C, Buchanan GR, Shurney W, Sarniak I, Fallon R, Chu JY, Pegelow CH, Wang W, Casella JF, Resar LS, Berman B, Adamkiewicz T, Hsu LL, Ohene-Frempong K, Smith-Whitley K, Mahoney D, Scott JP, Woods GM, Watanabe M, Debaun MR (2002). Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr 140:348-354.
70. Cohen AR, Martin MB, Silber JH, Kim HC, Ohene-Frempong K, Schwartz E (1992). A modified transfusion program for prevention of stroke in sickle cell disease. Blood 79:1657-1661.
71. Ware RE, Steinberg MH, Kinney TR (1995). Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia. Am J Hematol 50:140-143.
72. Adams HP Jr AR, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ (2003). Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 34:1056-1083.
73. McQuaker IG, Jaspan T, McConachie NS, Dolan G (1999). Coil embolization of cerebral aneurysms in patients with sickling disorders. Br J Haematol 106:388-390.
74. Anson JA, Koshy M, Ferguson L, Crowell RM (1991). Subarachnoid hemorrhage in sickle-cell disease. J Neurosurg 75:552-558.
75. Firth PG, Peterfreund RA (2000). Management of multiple intracranial aneurysms: neuroanesthetic considerations of sickle cell disease. J Neurosurg Anesth 12:366-371.
76. Fryer RH, Anderson RC, Chiriboga CA, Feldstein NA (2003). Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure. Pediatr Neurol 29:124-130.
77. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR (1995). Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332: 1317-1322.
78. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M (2003). Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289:1645-1651.
79. Wang W, Wynn LW, Rogers ZR, et al. (2001). A two-year pilot trial of hydroxyurea in very young children with sickle cell anemia. J Pediatr 139:790-796.
80. Sumoza A, de Bisotti R, Sumoza D, Fairbanks V (2002). Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am J Hematol 71:161-165.
81. Bernaudin F, Verlhac S, Coic L, Lesprit E, Brugieres P, Reinert P (2005). Long-term follow-up of pediatric sickle cell disease patients with abnormal high velocities on transcranial Doppler. Pediatr Radiol 35:242-248.
82. Ware RE, Zimmerman SA, Sylvestre PB, Mortier NA, Davis JS, Treem WR, Schultz WH (2004). Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 145:346-352.
83. Walters MC, Patience M, Edwards S, Robertson S, McMurray M, Donfield S, Sullivan K (2004). Hematopoietic cell transplantation for sickle cell disease: updated results of the multicenter trial. Blood 104:105a.
84. Thame JR, Hambleton IR, Serjeant GR (2001). RBC transfusion in sickle cell anemia (HbSS): experience from the Jamaican Cohort Study. Transfusion 41:596-601.
85. Vichinsky EP (2001). Current issues with blood transfusions in sickle cell disease. Semin Hematol 38:14-22.
86. Styles LA, Vichinsky E (1994). Effects of a long-term transfusion regimen on sickle cell-related illnesses. J Pediatr 125:909-911.
87. Fergusson D, Hebert PC, Lee SK, Walker CR, Barrington KJ, Joseph L, Blajchman MA, Shapiro S (2003). Clinical outcomes following institution of universal leukoreduction of blood transfusions for premature infants. JAMA 289:1950-1956.
88. AuBuchon JP, Birkmeyer JD, Busch MP (1997). Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med 127:904-909.
89. Busch MP (2000). HIV, HBV and HCV: new developments related to transfusion safety. Vox Sang 78(2 Suppl):253-256.
90. Murthy KK, Henrard DR, Eichberg JW, Cobb KE, Busch MP, Allain JP, Alter HJ (1999). Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Transfusion 39:688-693.
91. Laperche S, Le Marrec N, Simon N, Bouchardeau F, Defer C, Maniez-Montreuil M, Levayer T, Zappitelli JP, Lefrere JJ (2003). A new HCV core antigen assay based on disassociation of immune complexes: an alternative to molecular biology in the diagnosis of early HCV infection. Transfusion 43:958-962.
92. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V (2002). Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 42:37-43.
93. Tahhan HR, Holbrook CT, Braddy LR, Brewer LD, Christie JD (1994). Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion 34:562-569.
94. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B (1990). Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood [see comments]. N Engl J Med 322:1617-1621.
95. Rosse WF, Gallagher D, Kinney TR, Castro O, Dosik H, Moohr J, Wang W, Levy PS (1990). Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 76:1431-1437.
96. Fisher TC (2000). PEG-coated red blood cells-simplifying blood transfusion in the new millennium? Immunohematology 16:37-48.
97. Habler O, Pape A, Meier J, Zwissler B (2005). Artificial oxygen carriers as an alternative to red blood cell transfusion. Anaesthesist 54(8):741-754.
98. Maevsky E, Ivanitsky G, Bogdanova L, Axenova O, Karmen N, Zhiburt E, Senina R, Pushkin S, Maslennikov I, Orlov A, Marinicheva I (2005). Clinical results of Perftoran application: present and future. Artif Cells Blood Substit Immobil Biotechnol 33:37-46.
99. Lowe KC (2003). Engineering blood: synthetic substitutes from fluorinated compounds. Tissue Eng 9:389-399.
100. Gonzalez P (1997). Nuclear medicine test reports. Rev Med Chil 125:1112-1113.
101. Lanzkron S, Moliterno AR, Norris EJ, Gould SA, Segal J, Nuermberger EL, Ness PM (2002). Polymerized human Hb use in acute chest syndrome: a case report. Transfusion 42:1422-1427.
102. Finch CA (1982). The detection of iron overload. N Engl J Med 307:1702-1704.
103. Harmatz P, Butensky E, Quirolo K, Williams R, Ferrell L, Moyer T, Golden D, Neumayr L, Vichinsky E (2000). Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 96:76-79.
104. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD (2004). Myocardial iron loading in transfusiondependent thalassemia and sickle cell disease. Blood 103:1934-1936.
105. Beard JL, Dawson H, Pinero DJ (1996). Iron metabolism: a comprehensive review. Nutr Rev 54:295-317.
106. Bourantas KL, Dalekos GN, Makis A, Chaidos A, Tsiara S, Mavridis A (1998). Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol 61:49-54.
107. Ballas SK (2001). Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 38:30-36.
108. Bonkovsky HL, Slaker DP, Bills EB, Wolf DC (1990). Usefulness and limitations of laboratory and hepatic imaging studies in iron-storage disease. Gastroenterology 99:1079-1091.
109. Brittenham GM, Badman DG (2003). Noninvasive measurement of iron: report of an NIDDK workshop. Blood 101:15-19.
110. Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A (2003). Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 121:938-948.
111. Carneiro AA, Fernandes JP, de Araujo DB, Elias J Jr, Martinelli AL, Covas DT, Zago MA, Angulo IL, St Pierre TG, Baffa O (2005). Liver iron concentration evaluated by two magnetic methods: magnetic resonance imaging and magnetic susceptometry. Magn Reson Med 54:122-128.
112. Fischer R, Tiemann CD, Engelhardt R, Nielsen P, Durken M, Gabbe EE, Janka GE (1999). Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry. Am J Hematol 60:289-299.
113. Nielsen P, Engelhardt R, Duerken M, Janka GE, Fischer R (2000). Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases. Transfus Sci 23:257-258.
114. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R (2005). Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105:855-861.
115. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, van Rossum AC, Shaw LJ, Yucel EK (2004). Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J 25:1940-1965.
116. Davis BA, Porter JB (2000). Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 95:1229-1236.
117. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A (2004). Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89:1187-1193.
118. Beutler E, Hoffbrand AV, Cook JD (2003). Iron deficiency and overload. Hematology (Am Soc Hematol Educ Program) 45:40-61.
119. Hershko C, Cappellini MD, Galanello R, Piga A, Tognoni G, Masera G (2004). Purging iron from the heart. Br J Haematol 125:545-551.
120. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R (2003). Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 43:565-572.
121. Adams DM, Schultz WH, Ware RE, Kinney TR (1996). Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients. J Pediatr Hematol Oncol 18:46-50.
122. Marques Junior JF, Saad ST, Costa FF, Souza CA (1995). Automated erythrocytapheresis in sickle cell anaemia. Int J Artif Organs 18:345-346.
123. Kim HC, Dugan NP, Silber JH, Martin MB, Schwartz E, Ohene-Frempong K, Cohen AR (1994). Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood 83:1136-1142.
124. Singer ST, Quirolo K, Nishi K, Hackney-Stephens E, Evans C, Vichinsky EP (1999). Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J Clin Apheresis 14:122-125.
125. Hilliard LM, Williams BF, Lounsbury AE, Howard TH (1998). Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients. Am J Hematol 59:28-35.
126. Raj A, Bertolone S, Bond S, Burnett D, Denker A (2005). Cathlink 20: a subcutaneous implanted central venous access device used in children with sickle cell disease on long-term erythrocytapheresis-a report of low complication rates. Pediatr Blood Cancer 44:669-672.